Seigo Korematsu

Dr. Seigo Korematsu

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
SKSeigo Korematsu
Seigo Korematsu
SUShin-Ichi Uchiyama
Shin-Ichi Uchiyama
HMHiroaki Miyahara
Hiroaki Miyahara
TNTomokazu Nagakura
Tomokazu Nagakura
NONaho Okazaki
Naho Okazaki
TITatsuro Izumi
Tatsuro Izumi
The central nervous system (CNS) inflammation of Kawasaki disease (KD) has not been sufficiently evaluated in spite of the complications of irritability and CSF pleocytosis. Cerebrospinal fluid (CSF) and serum inflammatory cytokine values were simultaneously examined in 10 patients (2.6 +/- 2.1 year of age) during the acute phase. They were all irritable and demonstrated mild consciousness disturbance. The CSF IL6 was elevated (>3.0 pg/mL) in 6 patients, and 4 of them showed higher CSF than serum values. The CSF sTNFR1 was elevated (>0.5 microg/mL) in 6 patients, and 1 showed higher CSF than serum values. These CSF cytokine (IL6; 81.4 +/- 192.8 pg/mL, sTNFR1; 1.1 +/- 0.8 microg/mL) and CSF/serum ratio (IL6; 2.8 +/- 5.2, sTNFR1 0.4 +/- 0.4) in patients with KD were the same as those of patients with acute encephalitis/acute encephalopathy. The differences in the inflammatory cytokine value between CSF and serum suggest that the degree of systemic vasculitis is different between CSF and the circulating blood, and some patients with KD showed a higher degree of CSF inflammation.

1 August 2009 in Vaccine
Verified
Journal Article
Closed access
SKSeigo Korematsu
Seigo Korematsu
HMHiroaki Miyahara
Hiroaki Miyahara
TKTatsuya Kawano
Tatsuya Kawano
HYHiroshi Yamada
Hiroshi Yamada
KAKensuke Akiyoshi
Kensuke Akiyoshi
TITatsuro Izumi
Tatsuro Izumi

11 February 2008 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
SKSeigo Korematsu
Seigo Korematsu
HMHiroaki Miyahara
Hiroaki Miyahara
TNTomokazu Nagakura
Tomokazu Nagakura
SSSoichi Suenobu
Soichi Suenobu
TITatsuro Izumi
Tatsuro Izumi

26 April 2010 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
SKSeigo Korematsu
Seigo Korematsu
KYKyoko Yamamoto
Kyoko Yamamoto
TNTomokazu Nagakura
Tomokazu Nagakura
HMHiroaki Miyahara
Hiroaki Miyahara
NONaho Okazaki
Naho Okazaki
TITatsuro Izumi
Tatsuro Izumi
Korematsu S, Yamamoto K, Nagakura T, Miyahara H, Okazaki N, Akiyoshi K, Maeda T, Suenobu S-i, Izumi T. The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma.Pediatr Allergy Immunol 2010: 21: 489–492.© 2010 John Wiley & Sons A/S To elucidate the mechanisms of intractable pediatric bronchial asthma and the indication of low-dose erythromycin (EM) therapy, the serum chemokine levels of and the angiogenic factor were evaluated in 55 pediatric patients with bronchial asthma; 7.4 ± 3.5 yr old, who had been treated with inhaled steroid, leukotriene receptor antagonist, theophylline and others for more than a year. Both the levels of interleukin (IL) 8 (p = 0.036) and vascular endothelial growth factor (VEGF) (p = 0.005) were higher in patients with severe type than those of patients with the milder type, while other chemokine levels such as serum eotaxin and MCP1 did not show the correlation with the severity of bronchial asthma. Induction of therapy with low-dose EM induced improvement of the clinical symptoms in patients with severe type and decrease of their serum chemokine levels: IL8; from 736 ± 88 to 75 ± 85 pg/ml (p < 0.0005), and VEGF; from 352.0 ± 160.5 to 132.2 ± 59.9 pg/ml (p = 0.021) within the next 6 months. Moreover, low-dose EM resulted in a decreased daily peak-trough fluctuation rate of the serum theophylline concentration; (Cmax − Cmin)/Cmin, from 1.3 ± 0.5 to 0.5 ± 0.3, which led to the maintenance of effective serum levels. These results indicated that IL8 and VEGF affect the severity of standard therapies resistance intractable bronchial asthma. Through the suppression of these chemokines and maintenance of effective theophylline levels, low-dose EM therapy improves the symptoms of bronchial asthma.

1 September 2012 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
SKSeigo Korematsu
Seigo Korematsu
YOYoko Ohta
Yoko Ohta
NTNaotaka Tamai
Naotaka Tamai
MTMasahiro Takeguchi
Masahiro Takeguchi
CGChika Goto
Chika Goto
TITatsuro Izumi
Tatsuro Izumi
The interaction of matrix metalloproteinase (MMP)-9 and tissue inhibitor of matrix metalloproteinase-1 has been implicated in the formation of coronary aneurysms in Kawasaki disease. MMP-9 and tissue inhibitor of matrix metalloproteinase-1 were distributed predominantly in the granulocytes and platelets, respectively, in patients with Kawasaki disease. The plasma values of MMP-9 correlated positively with the circulating neutrophil count. Inhibiting the activity of granulocytes and maintaining the platelet activity might prevent coronary aneurysms.

1 January 2017 in Asia Pacific Allergy
Verified
Journal Article
Open access
PDF file
SKSeigo Korematsu
Seigo Korematsu
MFMichiko Fujitaka
Michiko Fujitaka
MOMika Ogata
Mika Ogata
MZMasafumi Zaitsu
Masafumi Zaitsu
CMChikako Motomura
Chikako Motomura
HOHiroshi Odajima
Hiroshi Odajima
Korematsu S, et al. Asia Pac Allergy. 2017 Jan;7(1):37-41. https://doi.org/10.5415/apallergy.2017.7.1.37